Welcome to our dedicated page for Citius Pharmaceuticals SEC filings (Ticker: CTXR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nevada-incorporated biopharmaceutical issuer (Commission File Number 001-38174), Citius Pharmaceuticals reports material events, financing transactions, and other corporate developments through forms such as Form 8-K and registration statements on Form S-3.
In its recent Form 8-K filings, Citius Pharmaceuticals has described securities purchase agreements for registered direct offerings of common stock, pre-funded warrants and common warrants, including details on exercise prices, terms, placement agent arrangements and intended use of proceeds. The company states that net proceeds are expected to support the commercial launch of LYMPHIR, milestone and regulatory payments, development initiatives for its product candidates, and general corporate purposes.
Other 8-K filings referenced by the company include notices of compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement, as well as disclosures about corporate presentations and earnings press releases furnished under Regulation FD and Item 2.02. Together, these filings offer insight into CTXR’s capital strategy, listing status and communication practices with investors.
Through Stock Titan, users can review CTXR’s current and historical SEC documents, including registration statements that underpin shelf offerings and the associated prospectus supplements. The platform pairs these filings with AI-powered summaries designed to clarify key terms, highlight significant financing structures, and explain how reported events relate to the company’s commercialization of LYMPHIR and its late-stage pipeline assets Mino-Lok and CITI-002 (Halo-Lido). This makes it easier to understand complex documents such as 8-Ks, S-3 registration statements, and related exhibits without reading every line of legal text.